Articles amb requisits d'accés públic - Yulia Y. MaxuitenkoMés informació
No està disponible en cap lloc: 1
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
AB Coley, A Ward, AB Keeton, X Chen, Y Maxuitenko, A Prakash, F Li, ...
Advances in cancer research 153, 131-168, 2022
Requisits: US National Institutes of Health
Disponibles en algun lloc: 18
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity
GA Piazza, AB Keeton, HN Tinsley, BD Gary, JD Whitt, B Mathew, ...
Cancer Prevention Research 2 (6), 572-580, 2009
Requisits: US National Institutes of Health
Colon tumor cell growth–inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition
HN Tinsley, BD Gary, J Thaiparambil, N Li, W Lu, Y Li, YY Maxuitenko, ...
Cancer Prevention Research 3 (10), 1303-1313, 2010
Requisits: US National Institutes of Health
Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine
JV Thottassery, V Sambandam, PW Allan, JA Maddry, YY Maxuitenko, ...
Cancer chemotherapy and pharmacology 74, 291-302, 2014
Requisits: US National Institutes of Health
Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors
Z Qu, S Van Ginkel, AM Roy, L Westbrook, M Nasrin, Y Maxuitenko, ...
Cancer research 68 (15), 6232-6240, 2008
Requisits: US National Institutes of Health
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity
GA Piazza, A Ward, X Chen, Y Maxuitenko, A Coley, NS Aboelella, ...
Drug discovery today 25 (8), 1521-1527, 2020
Requisits: US National Institutes of Health
Exploiting RAS nucleotide cycling as a strategy for drugging RAS-driven cancers
TE Mattox, X Chen, YY Maxuitenko, AB Keeton, GA Piazza
International Journal of Molecular Sciences 21 (1), 141, 2019
Requisits: US National Institutes of Health
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer
A Adamska, A Domenichini, E Capone, V Damiani, BG Akkaya, KJ Linton, ...
Journal of Experimental & Clinical Cancer Research 38, 1-14, 2019
Requisits: AIRC Foundation for Cancer Research in Italy
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
AB Ward, AB Keeton, X Chen, TE Mattox, AB Coley, YY Maxuitenko, ...
MedComm 1 (2), 121-128, 2020
Requisits: US National Institutes of Health
From celecoxib to a novel class of phosphodiesterase 5 inhibitors: Trisubstituted pyrazolines as novel phosphodiesterase 5 inhibitors with extremely high potency and …
M Abdel-Halim, S Sigler, NAS Racheed, A Hefnawy, RK Fathalla, ...
Journal of Medicinal Chemistry 64 (8), 4462-4477, 2021
Requisits: US National Institutes of Health
Inhibition of the lysophosphatidylinositol transporter ABCC1 reduces prostate cancer cell growth and sensitizes to chemotherapy
A Emmanouilidi, I Casari, B Gokcen Akkaya, T Maffucci, L Furic, F Guffanti, ...
Cancers 12 (8), 2022, 2020
Requisits: US National Institutes of Health, Prostate Cancer UK
Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea
MA Coburn, S Brueggemann, S Bhatia, B Cheng, BDL Li, XL Li, ...
Cancer letters 312 (1), 82-90, 2011
Requisits: US National Institutes of Health
Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin
KJ Lee, WCL Chang, X Chen, J Valiyaveettil, V Ramirez-Alcantara, ...
Cancer Prevention Research 14 (11), 995-1008, 2021
Requisits: US National Institutes of Health
Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity
GA Piazza, X Chen, A Ward, A Coley, G Zhou, DJ Buchsbaum, ...
Oncology Signaling 3, 1-6, 2020
Requisits: US National Institutes of Health
Novel non-cyclooxygenase inhibitory derivative of Sulindac inhibits breast cancer cell growth in vitro and reduces mammary tumorigenesis in rats
HN Tinsley, B Mathew, X Chen, YY Maxuitenko, N Li, WM Lowe, JD Whitt, ...
Cancers 15 (3), 646, 2023
Requisits: US National Institutes of Health
A novel Pan-RAS inhibitor with a unique mechanism of action blocks tumor growth in mouse models of GI cancer
JB Foote, TE Mattox, AB Keeton, X Chen, FT Smith, KL Berry, T Holmes, ...
bioRxiv, 2023.05. 17.541233, 2023
Requisits: US National Institutes of Health
Colon tumor cell growth inhibitory activity of sulindac sulfide and other NSAIDs is associated with PDE5 inhibition
HN Tinsley, BD Gary, J Thaiparambil, N Li, W Lu, Y Li, YY Maxuitenko, ...
Cancer prevention research (Philadelphia, Pa.) 3 (10), 1303, 2010
Requisits: US National Institutes of Health
Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity
S Ramesh, P Johnson, K Fadlalla, A Moore, CH Huang, K Berry, ...
Cancer Insight 3 (1), 42-54, 2023
Requisits: US National Institutes of Health
Cancer Insight
S Ramesh, P Johnson, K Fadlalla, A Moore, CH Huang, K Berry, ...
Cancer 2 (2), 42-54, 2023
Requisits: US National Institutes of Health
Les dades de publicació i de finançament es determinen automàticament per mitjà d'un programa informàtic